Natixis Advisors LLC Has $39.34 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Natixis Advisors LLC grew its stake in Kenvue Inc. (NYSE:KVUE) by 3.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,842,646 shares of the company’s stock after buying an additional 69,683 shares during the period. Natixis Advisors LLC’s holdings in Kenvue were worth $39,341,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Huntington National Bank raised its stake in Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after buying an additional 871 shares during the period. Handelsbanken Fonder AB raised its stake in Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock worth $15,846,000 after buying an additional 21,222 shares during the period. Alberta Investment Management Corp raised its stake in Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock worth $12,445,000 after buying an additional 109,700 shares during the period. Longbow Finance SA raised its stake in shares of Kenvue by 5.0% in the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock valued at $5,990,000 after purchasing an additional 13,287 shares during the period. Finally, CORDA Investment Management LLC. lifted its holdings in shares of Kenvue by 1.4% in the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company’s stock valued at $26,754,000 after purchasing an additional 17,466 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 1.6 %

NYSE KVUE opened at $22.81 on Monday. The company has a market cap of $43.59 billion, a PE ratio of 43.03, a PEG ratio of 2.62 and a beta of 1.25. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The stock has a 50 day moving average of $21.84 and a 200-day moving average of $22.39.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on KVUE. Piper Sandler upped their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.